Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells

Open access
Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun · 2018 · Cell Death & Disease

Abstract

Testing new ways to identify untapped opportunities for glioblastoma therapies remains highly significant. Amplification and overexpression of MDM2 gene is frequent in glioblastoma and disrupting the MDM2−p53 interaction is a promising strategy to treat the cancer. RG7112 is the first-in class inhibitor and recently discovered AMG232 is the most potent MDM2 inhibitor known to date. Here, we compared the effects of these two clinical MDM2 inhibitors in six glioblastoma cell lines and ten patient-derived glioblastoma stem cells. Targeted sequencing of the TP53, MDM2 genes and whole transcriptome analysis were conducted to verify genetic status associated with sensitivity and resistance to the drugs. Although TP53 wild-type glioblastoma cell lines are similarly sensitive to AMG232 and RG7112, we found that four TP53 wild-type out of ten patient-derived glioblastoma cells are much more sensitive to AMG232 than RG7112 (average IC 50 of 76 nM vs. 720 nM). Among these, 464T stem cells containing MDM2 gene amplification were most sensitive to AMG232 with IC 50 of 5.3 nM. Moreover, AMG232 exhibited higher selectivity against p53 wild-type cells over p53 mutant stem cells compared to RG7112 (average selectivity of 512-fold vs. 16.5-fold). Importantly, we also found that AMG232 is highly efficacious in three-dimensional (3D) tumor spheroids growth and effectively inhibits the stemness-related factors, Nestin and ZEB1. Our data provide new evidence that glioblastoma stem cells have high susceptibility to AMG232 suggesting the potential clinical implications of MDM2 inhibition for glioblastoma treatment. These will facilitate additional preclinical and clinical studies evaluating MDM2 inhibitors in glioblastoma and direct further efforts towards developing better MDM2-targeted therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-018-0825-1

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The effect of MDM2 inhibitors, RG7112 and AMG232 in glioblastoma cell lines. a Chemical structures of RG7112 and AMG232. b, c Cell numbers of U373MG, LN18, U251MG, A1207, DBTRG-05MG, and U87MG cells treated with different concentrations (0.07–54 μM) of RG7112 or AMG232 for 72 h were evaluated by quantifying image-based cell counting. Nonlinear regression analyses of dose−response curves are shown (n = 3). Error bars represent standard deviation (SD). d The IC50 values obtained from dose−response curves are shown. Each bars represent mean (n = 3) and 95% confidence interval (CI). e IC50 values of TP53 mutant cell lines (n = 3) and TP53 wild-type cell lines (n = 3) to RG7112 and AMG232 are shown. Data represent the mean and SD error (*p < 0.01). f An image-based immunofluorescence assay for p21 (green), p53 (red) and DAPI (blue) in A1207 cells treated with DMSO, RG7112 (2 μM), AMG232 (2 μM), and Camptothecin (10 μM) for 72 h are shown. g p21 fluorescence intensity measurements for A1207 cells treated with increasing concentrations of RG7112 or AMG232 for 72 h are shown. The Z-factor for 18 μM RG7112 and 18 μM AMG232 in A1207 cells are indicated. h The mean percentage of p21-positive cells (n = 3, SD) for six glioblastoma cell lines treated with DMSO, RG7112 (2 μM), AMG232 (2 μM) for 72 h are shown
Fig. 1 The effect of MDM2 inhibitors, RG7112 and AMG232 in glioblastoma cell lines. a Chemical structures of RG7112 and AMG232. b, c Cell numbers of U373MG, LN18, U251MG, A1207, DBTRG-05MG, and U87MG cells treated with different concentrations (0.07–54 μM) of RG7112 or AMG232 for 72 h were evaluated by quantifying image-based cell counting. Nonlinear regression analyses of dose−response curves are shown (n = 3). Error bars represent standard deviation (SD). d The IC50 values obtained from dose−response curves are shown. Each bars represent mean (n = 3) and 95% confidence interval (CI). e IC50 values of TP53 mutant cell lines (n = 3) and TP53 wild-type cell lines (n = 3) to RG7112 and AMG232 are shown. Data represent the mean and SD error (*p < 0.01). f An image-based immunofluorescence assay for p21 (green), p53 (red) and DAPI (blue) in A1207 cells treated with DMSO, RG7112 (2 μM), AMG232 (2 μM), and Camptothecin (10 μM) for 72 h are shown. g p21 fluorescence intensity measurements for A1207 cells treated with increasing concentrations of RG7112 or AMG232 for 72 h are shown. The Z-factor for 18 μM RG7112 and 18 μM AMG232 in A1207 cells are indicated. h The mean percentage of p21-positive cells (n = 3, SD) for six glioblastoma cell lines treated with DMSO, RG7112 (2 μM), AMG232 (2 μM) for 72 h are shownCC BY · PubMed Central
Fig. 2 Reactivation of p53 is associated with the sensitivity of glioblastoma cells to the MDM2 inhibitors. a U138MG, LN18, and A1207 cells were treated with RG7112 for 12 h at the indicated concentrations. p21, MDM2, p53, and PARP levels were examined by immunoblotting. Actin was used as a loading control. b A1207 cells were transfected with control or p53 siRNA for 48 h prior to treatment with DMSO or 1 μM AMG232 for 12 h. The levels of p53 and p21 were examined by immunoblotting. Actin was used as a loading control. c A1207 cells transfected with control or p53 siRNA for 48 h were treated with different concentrations (0.014–10.8 μM) of RG7112 or AMG232 for 72 h were evaluated by quantifying image-based cell counting. Nonlinear regression analyses of dose−response curves are shown (n = 3, SD error). d The graph represents IC50 values comparing control and p53-depleted A1207 cells for RG7112 and AMG232. Data show mean and SD error (*p < 0.01)
Fig. 2 Reactivation of p53 is associated with the sensitivity of glioblastoma cells to the MDM2 inhibitors. a U138MG, LN18, and A1207 cells were treated with RG7112 for 12 h at the indicated concentrations. p21, MDM2, p53, and PARP levels were examined by immunoblotting. Actin was used as a loading control. b A1207 cells were transfected with control or p53 siRNA for 48 h prior to treatment with DMSO or 1 μM AMG232 for 12 h. The levels of p53 and p21 were examined by immunoblotting. Actin was used as a loading control. c A1207 cells transfected with control or p53 siRNA for 48 h were treated with different concentrations (0.014–10.8 μM) of RG7112 or AMG232 for 72 h were evaluated by quantifying image-based cell counting. Nonlinear regression analyses of dose−response curves are shown (n = 3, SD error). d The graph represents IC50 values comparing control and p53-depleted A1207 cells for RG7112 and AMG232. Data show mean and SD error (*p < 0.01)CC BY · PubMed Central
Fig. 3 The effect of MDM2 inhibitors, RG7112 and AMG232 in patient-derived glioblastoma stem cells. a An experiment design of high content analysis for patient-derived glioblastoma stem cells are represented. Ten patient-derived glioblastoma stem cells were isolated and grown as neurosphere as shown in upper left panel. Stem cells were cultured in laminin-coated 384-well plates (upper right panel) were treated with RG7112 and AMG232 (0.7 nM−50 μM) for 72 h and were analyzed by automated microscopy for image-based cell counting and p21 immunofluorescence assay. Representative images of p21 (green) and DAPI (blue) in 526T stem cells treated with DMSO, RG7112 (1.8 μM), AMG232 (1.8 μM) for 72 h are shown in lower panel. b p21 fluorescence intensity measurements for DMSO, RG7112 (1.8 μM), and AMG232 (1.8 μM)-treated cells (n = 3). The gray line indicates the threshold (Z-score = 1.5). c The mean percentage of p21-positive cells for ten patient-derived glioblastoma stem cells treated with DMSO, RG7112 (1.8 μM), and AMG232 (1.8 μM) for 72 h are shown. Data represent mean (n = 3) and SD error. d IC50 values comparing RG7112 and AMG232 in ten patient-derived glioblastoma stem cells obtained from dose−response curves are shown (n = 3, CI error, *p < 0.05, **p < 0.01). Nonlinear regression analysis for these data are shown in Supplementary Figure 6
Fig. 3 The effect of MDM2 inhibitors, RG7112 and AMG232 in patient-derived glioblastoma stem cells. a An experiment design of high content analysis for patient-derived glioblastoma stem cells are represented. Ten patient-derived glioblastoma stem cells were isolated and grown as neurosphere as shown in upper left panel. Stem cells were cultured in laminin-coated 384-well plates (upper right panel) were treated with RG7112 and AMG232 (0.7 nM−50 μM) for 72 h and were analyzed by automated microscopy for image-based cell counting and p21 immunofluorescence assay. Representative images of p21 (green) and DAPI (blue) in 526T stem cells treated with DMSO, RG7112 (1.8 μM), AMG232 (1.8 μM) for 72 h are shown in lower panel. b p21 fluorescence intensity measurements for DMSO, RG7112 (1.8 μM), and AMG232 (1.8 μM)-treated cells (n = 3). The gray line indicates the threshold (Z-score = 1.5). c The mean percentage of p21-positive cells for ten patient-derived glioblastoma stem cells treated with DMSO, RG7112 (1.8 μM), and AMG232 (1.8 μM) for 72 h are shown. Data represent mean (n = 3) and SD error. d IC50 values comparing RG7112 and AMG232 in ten patient-derived glioblastoma stem cells obtained from dose−response curves are shown (n = 3, CI error, *p < 0.05, **p < 0.01). Nonlinear regression analysis for these data are shown in Supplementary Figure 6CC BY · PubMed Central
Fig. 4 Integrated genome and high content analyses verify genetic status of patient-derived glioblastoma stem cells associated with high sensitivity to AMG232. a Location of TP53 gene mutation in six patient-derived glioblastoma stem cells. Green circles represent missense mutations and a black circle indicates a splice-site mutation. The amino acid change is indicated above each circle and the name of patient-derived glioblastoma stem cells is bracketed. b The graph shows MDM2 gene copy numbers in ten patient-derived glioblastoma stem cells. P value is indicated in the graph. c Scatter plots showing IC50 values of patient-derived glioblastoma stem cells to RG7112 and AMG232. The stem cells are classified according to TP53 mutation status. P value is indicated in the graph. d A map of gene-high content analysis association. Genetic status of TP53, MDM2, and IC50, p21 fold-changes of the MDM2 inhibitors in ten patient-derived glioblastoma cells are summarized. Color scales with IC50 and Z-score values are indicated. e 526T, 578T, and 775T stem cells were treated with RG7112 and AMG232 for 72 h at the indicated concentrations. p21, MDM2, and p53 levels were evaluated by immunoblotting. Actin was used as a loading control
Fig. 4 Integrated genome and high content analyses verify genetic status of patient-derived glioblastoma stem cells associated with high sensitivity to AMG232. a Location of TP53 gene mutation in six patient-derived glioblastoma stem cells. Green circles represent missense mutations and a black circle indicates a splice-site mutation. The amino acid change is indicated above each circle and the name of patient-derived glioblastoma stem cells is bracketed. b The graph shows MDM2 gene copy numbers in ten patient-derived glioblastoma stem cells. P value is indicated in the graph. c Scatter plots showing IC50 values of patient-derived glioblastoma stem cells to RG7112 and AMG232. The stem cells are classified according to TP53 mutation status. P value is indicated in the graph. d A map of gene-high content analysis association. Genetic status of TP53, MDM2, and IC50, p21 fold-changes of the MDM2 inhibitors in ten patient-derived glioblastoma cells are summarized. Color scales with IC50 and Z-score values are indicated. e 526T, 578T, and 775T stem cells were treated with RG7112 and AMG232 for 72 h at the indicated concentrations. p21, MDM2, and p53 levels were evaluated by immunoblotting. Actin was used as a loading controlCC BY · PubMed Central
Fig. 5 AMG232 suppresses Nestin, ZEB1 and stemness of patient-derived glioblastoma cells. a Three-dimensional (3D) tumor spheroids of 526T, 578T, and 775T patient-derived glioblastoma cells were treated with indicated concentrations of RG7112 and AMG232. Representative images show the response of 3D spheroids to RG7112 and AMG232 at day 14. b The sphere images were taken at 2-day intervals up to 14 days and the sizes were measured and analyzed. Data represent the mean (n = 3) and SD error. c 578T cells were treated with 0.1 μM AMG232 for 72 h and analyzed by immunoblotting (see Supplementary Figure 9). The steady-state levels of Nestin and ZEB1 relative to Actin were quantified. Data show the mean and error (n = 2, SD, *p < 0.05)
Fig. 5 AMG232 suppresses Nestin, ZEB1 and stemness of patient-derived glioblastoma cells. a Three-dimensional (3D) tumor spheroids of 526T, 578T, and 775T patient-derived glioblastoma cells were treated with indicated concentrations of RG7112 and AMG232. Representative images show the response of 3D spheroids to RG7112 and AMG232 at day 14. b The sphere images were taken at 2-day intervals up to 14 days and the sizes were measured and analyzed. Data represent the mean (n = 3) and SD error. c 578T cells were treated with 0.1 μM AMG232 for 72 h and analyzed by immunoblotting (see Supplementary Figure 9). The steady-state levels of Nestin and ZEB1 relative to Actin were quantified. Data show the mean and error (n = 2, SD, *p < 0.05)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 68

Metadata

Authors
Her, N.-G., Oh, J.-W., Oh, Y. J., Han, S., Cho, H. J., Lee, Y., Ryu, G. H., & Nam, D.-H.
Affiliations
  • Samsung Medical Center (KR)
  • Sungkyunkwan University (KR)
Corresponding author
  • Ryu, Gyu Ha
  • Nam, Do-Hyun
Venue
Cell Death & Disease
Published
2018-07-18
Volume
9
Issue
8
Pages
792-792
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2884639737
Cited by
68
References
52
Citations by year
2026: 2 · 2025: 8 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 14 · 2020: 9 · 2019: 3 · 2018: 2
FWCI
2.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Research Foundation (NRF-2015M3A9A7029740)
  • Ministry of Science, ICT and Future Planning (2015M3A9A7029740, NRF-2015M3A9A7029740)
  • Korea Health Industry Development Institute (HI14C3418)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
RG7112, MDM2 inhibitors, glioblastoma stem cells, p53-MDM2 interaction, MDM2 amplification, wild-type p53, drug sensitivity, drug selectivity, tumor spheroids, nestin, ZEB1
MeSH terms
Zinc Finger E-box-Binding Homeobox 1, Acetates, Enzyme Inhibitors, Glioblastoma, Humans, Mutation, Piperidones, Tumor Suppressor Protein p53, Apoptosis, Cell Line, Tumor, Imidazolines, Proto-Oncogene Proteins c-mdm2, Nestin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. https://app.cochat.ai/papers/10.1038/s41419-018-0825-1
The paper
Her, N.-G., Oh, J.-W., Oh, Y. J., Han, S., Cho, H. J., Lee, Y., Ryu, G. H., & Nam, D.-H. (2018). Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death & Disease. https://doi.org/10.1038/s41419-018-0825-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.